Literature DB >> 31063011

Sensitivity and Specificity of Alzheimer Type II Astrocytes in Hepatic Encephalopathy.

Apeksha N Agarwal1, Daniel D Mais1.   

Abstract

CONTEXT.—: Hepatic encephalopathy (HE) is associated with presence of type II astrocytes in the brain on the basis of observations made in single uncontrolled cases. This finding was subsequently demonstrated by in vitro studies with replication of microenvironment of HE by increase in ammonia levels. However, no human studies have been done correlating HE with type II astrocytes. OBJECTIVE.—: To determine the sensitivity and specificity of type II astrocytes in HE. DESIGN.—: This is a retrospective cohort study in which cases and controls were included. A database search was conducted to identify potential cases of hepatic encephalopathy during a 3-year period, as well as concomitant cases with altered mental status from other causes, liver disease, both, and neither. The presence of HE was determined according to standard clinical criteria, and a coronal section of basal ganglia was selected for examination from each case. Type II astrocytes were enumerated over 20 random high-power fields (HPFs). RESULTS.—: Twenty-one patients with HE were identified, with 35 patient controls (18 females, 38 males). Among the patients with HE there was a mean of 19.8 type II astrocytes in 20 HPFs. Patients with altered mental status without HE had an average of 7.2 type II astrocytes per 20 HPFs, and for those without altered mental status, the average was 2.8. For patients with hepatic insufficiency without HE, the average was 11, while for patients with normal hepatic function, the average was 4.1. Overall, for those without HE, the average was 5.4 type II astrocytes per 20 HPFs. CONCLUSIONS.—: At a cutoff of 5 or more type II astrocytes per 20 HPFs, sensitivity for HE was 85.7% and specificity was 68.6%. Alzheimer type II astrocytes were present in all cases of HE but were also present in a wide variety of patients without HE.

Entities:  

Mesh:

Year:  2019        PMID: 31063011     DOI: 10.5858/arpa.2018-0455-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Neuropathology of COVID-19 (neuro-COVID): clinicopathological update.

Authors:  Jerry J Lou; Mehrnaz Movassaghi; Dominique Gordy; Madeline G Olson; Ting Zhang; Maya S Khurana; Zesheng Chen; Mari Perez-Rosendahl; Samasuk Thammachantha; Elyse J Singer; Shino D Magaki; Harry V Vinters; William H Yong
Journal:  Free Neuropathol       Date:  2021-01-18

2.  Therapeutic potential of probiotics - Lactobacillus plantarum UBLP40 and Bacillus clausii UBBC07 on thioacetamide-induced acute hepatic encephalopathy in rats.

Authors:  Lalita Shahgond; Chirag Patel; Khushboo Thakur; Dipta Sarkar; Sanjeev Acharya; Priyanshi Patel
Journal:  Metab Brain Dis       Date:  2021-11-03       Impact factor: 3.584

Review 3.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

Review 4.  Copper Dyshomeostasis in Neurodegenerative Diseases-Therapeutic Implications.

Authors:  Grażyna Gromadzka; Beata Tarnacka; Anna Flaga; Agata Adamczyk
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 5.  The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis.

Authors:  So Yeong Cheon; Juhyun Song
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

Review 6.  Hepatic Encephalopathy: From Metabolic to Neurodegenerative.

Authors:  Rafael Ochoa-Sanchez; Farzaneh Tamnanloo; Christopher F Rose
Journal:  Neurochem Res       Date:  2021-06-15       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.